Edwards Lifesciences Corp (EW) shareholders
EWNYSEOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 10/3060% above fair value
$107.15+1.35 (+1.28%)
Close on Nov 13, 2026Market cap $61.76BP/E 60.5Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
91.0%
524M of 576M shares
Institutional holders
1,330
164 new, 101 sold out
Net institutional buying
21M
In Q2 2026
Insider trades, 12 months
0 buys · 55 sales
Net sold $34.06M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 44,267,376 | 7.50% | 13G (passive) amendment | Sep 30, 2025 |
| Vanguard Capital Management | 43,477,533 | 7.54% | 13G (passive) | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of EW | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 58,789,433 | 10.20% | $5.32B | +6,198,500 | 0.08% |
| Vanguard Capital Management LLC | 37,615,952 | 6.53% | $3.40B | −111,840 | 0.07% |
| Vanguard Portfolio Management LLC | 26,411,402 | 4.58% | $2.39B | +4,384 | 0.11% |
| State Street Corp | 26,321,940 | 4.57% | $2.38B | +25,541 | 0.07% |
| JPMorgan Chase & Co | 22,783,175 | 3.95% | $2.08B | +1,038,463 | 0.11% |
| Wellington Management Group Llp | 16,827,967 | 2.92% | $1.52B | −5,183,134 | 0.26% |
| Geode Capital Management, LLC | 15,437,251 | 2.68% | $1.39B | +2,303,474 | 0.07% |
| Bank of New York Mellon Corp | 14,084,483 | 2.44% | $1.27B | −2,653,065 | 0.21% |
| DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main | 13,002,965 | 2.26% | $1.18B | +191,063 | 0.90% |
| Ninety One UK Ltd | 12,337,502 | 2.14% | $1.12B | −58,641 | 2.50% |
| Aristotle Capital Management, LLC | 8,665,712 | 1.50% | $783.91M | New | 1.64% |
| Alliancebernstein L.P. | 8,660,416 | 1.50% | $693.53M | +5,193,061 | 0.23% |
| FMR LLC | 8,435,949 | 1.46% | $763.12M | −6,067,821 | 0.03% |
| Norges Bank | 8,373,783 | 1.45% | $757.49M | New | 0.08% |
| Brown Advisory Inc | 7,365,987 | 1.28% | $666.33M | +336,475 | 1.03% |
| Bank Of America Corp /De/ | 6,692,424 | 1.16% | $605.40M | +2,809,005 | 0.04% |
| Artisan Partners Limited Partnership | 6,625,703 | 1.15% | $599.36M | +1,424,559 | 0.95% |
| Morgan Stanley | 6,339,368 | 1.10% | $573.46M | −721,508 | 0.03% |
| Deutsche Bank AG\ | 5,710,284 | 0.99% | $516.55M | −344,739 | 0.15% |
| Arrowstreet Capital, Limited Partnership | 5,677,344 | 0.98% | $513.57M | +3,786,485 | 0.23% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 1,330 | 524M | 91.0% | 164 / 469 | 466 / 101 | 70M | 48M |
| Q1 2026 | 1,290 | 504M | 87.5% | 113 / 456 | 459 / 119 | 118M | 51M |
| Q4 2025 | 1,315 | 507M | 88.0% | 186 / 423 | 476 / 100 | 46M | 61M |
| Q3 2025 | 1,254 | 525M | 91.2% | 114 / 446 | 441 / 106 | 74M | 54M |
| Q2 2025 | 1,259 | 506M | 87.8% | 164 / 421 | 459 / 94 | 49M | 48M |
| Q1 2025 | 1,206 | 506M | 87.8% | 124 / 387 | 487 / 122 | 46M | 39M |
| Q4 2024 | 1,226 | 503M | 87.3% | 191 / 352 | 501 / 141 | 66M | 50M |
| Q3 2024 | 1,195 | 491M | 85.2% | 142 / 371 | 498 / 227 | 125M | 86M |
| Q2 2024 | 1,296 | 503M | 87.3% | 123 / 461 | 467 / 91 | 30M | 35M |
| Q1 2024 | 1,278 | 512M | 88.8% | 161 / 432 | 462 / 109 | 53M | 40M |
| Q4 2023 | 1,245 | 499M | 86.5% | 173 / 378 | 500 / 132 | 62M | 54M |
| Q3 2023 | 1,221 | 493M | 85.5% | 108 / 432 | 465 / 152 | 38M | 40M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
834 funds held EW in Q2 2026, 52% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of EW | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 18,279,615 | 3.17% | $1.65B | 0.07% | Jun 30, 2026 |
| Vanguard 500 Index Fund | 14,919,502 | 2.59% | $1.35B | 0.08% | Jun 30, 2026 |
| Vanguard Mid-Cap Index Fund | 12,476,018 | 2.16% | $1.13B | 0.50% | Jun 30, 2026 |
| Vanguard Health Care Fund | 11,357,910 | 1.97% | $977.58M | 2.56% | Jul 31, 2026 |
| iShares Core S&P 500 ETF | 7,920,729 | 1.37% | $716.51M | 0.08% | Jun 30, 2026 |
| Fidelity 500 Index Fund | 7,426,109 | 1.29% | $642.14M | 0.08% | May 31, 2026 |
| Vanguard Value Index Fund | 5,475,762 | 0.95% | $495.34M | 0.19% | Jun 30, 2026 |
| Vanguard Mid-Cap Growth Index Fund | 4,411,246 | 0.77% | $399.04M | 1.15% | Jun 30, 2026 |
| State Street(R) Health Care Select Sector SPDR(R) ETF | 4,067,877 | 0.71% | $367.98M | 0.91% | Jun 30, 2026 |
| JPMorgan U.S. Equity Fund | 3,216,213 | 0.56% | $290.94M | 0.87% | Jun 30, 2026 |
| Vanguard Institutional Index Fund | 3,125,977 | 0.54% | $282.78M | 0.08% | Jun 30, 2026 |
| Vanguard Windsor Ii Fund | 3,121,221 | 0.54% | $268.64M | 0.40% | Jul 31, 2026 |
| iShares Russell Mid-Cap ETF | 2,343,629 | 0.41% | $212.00M | 0.37% | Jun 30, 2026 |
| Fidelity Mid Cap Index Fund | 2,174,871 | 0.38% | $187.19M | 0.36% | Jul 31, 2026 |
| Invesco S&P 500 Equal Weight ETF | 2,167,082 | 0.38% | $186.52M | 0.19% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Bernard J. Zovighian | CEO, Director | 111,494 | 0.02% | Nov 9, 2026 |
| Andrew M. Dahl | SVP, Corporate Controller | 14,606 | 0.00% | Nov 13, 2026 |
| Daniel J. Lippis | CVP, TAVR | 40,034 | 0.01% | Nov 10, 2026 |
| Donald E. Bobo Jr | CVP,Strategy/Corp Development | 152,379 | 0.03% | Nov 9, 2026 |
| Wayne Markowitz | CVP, JAPAC | 19,371 | 0.00% | Sep 14, 2026 |
| Daveen Chopra | CVP, TMTT, Surgical & IHFM | 43,926 | 0.01% | Sep 11, 2026 |
| Annette Bruls | CVP, EMEACLA | 17,984 | 0.00% | Aug 28, 2026 |
| Theodora Mistras | CVP, Chief Financial Officer | 87,595 | 0.02% | Jul 10, 2026 |
| Scott B. Ullem | CVP, Chief Financial Officer | 313,058 | 0.05% | May 11, 2026 |
| Larry L. Wood | Global President TAVR & Surg | 207,049 | 0.04% | Aug 18, 2025 |
| Leslie C. Davis | Director | 9,834 | 0.00% | May 8, 2026 |
| Nicholas J. Valeriani | Director | 84,423 | 0.01% | May 8, 2026 |
| Kieran Gallahue | Director | 82,907 | 0.01% | May 8, 2026 |
| Steven R. Loranger | Director | 83,305 | 0.01% | May 8, 2026 |
| Paul A. Laviolette | Director | 17,552 | 0.00% | May 8, 2026 |
| David T. Feinberg | Director | 9,087 | 0.00% | May 8, 2026 |
| Heisz Leslie Stone | Director | 34,199 | 0.01% | May 8, 2026 |
| Ramona Sequeira | Director | 20,855 | 0.00% | May 8, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Andrew M. Dahl SVP, Corporate Controller | Nov 13, 2026 | Tax withholding | −101 | $105.80 | $10.69K | 14,606 |
| Daniel J. Lippis CVP, TAVR | Nov 10, 2026 | Sale(10b5-1 plan) | −619 | $104.25 | $64.53K | 40,034 |
| Daniel J. Lippis CVP, TAVR | Nov 10, 2026 | Option exercise | +619 | $72.68 | $44.99K | 40,653 |
| Bernard J. Zovighian CEO, Director | Nov 9, 2026 | Sale(10b5-1 plan) | −13,916 | $102.78 | $1.43M | 98,845 |
| Bernard J. Zovighian CEO, Director | Nov 9, 2026 | Sale(10b5-1 plan) | −9,184 | $103.39 | $949.49K | 112,761 |
| Bernard J. Zovighian CEO, Director | Nov 9, 2026 | Option exercise | +23,100 | $72.68 | $1.68M | 121,945 |
| Donald E. Bobo Jr CVP,Strategy/Corp Development | Nov 9, 2026 | Sale(10b5-1 plan) | −48,900 | $103.05 | $5.04M | 22,798 |
| Donald E. Bobo Jr CVP,Strategy/Corp Development | Nov 9, 2026 | Option exercise | +48,900 | $72.68 | $3.55M | 71,698 |
| Daniel J. Lippis CVP, TAVR | Oct 8, 2026 | Sale(10b5-1 plan) | −619 | $85.65 | $53.02K | 40,034 |
| Daniel J. Lippis CVP, TAVR | Oct 8, 2026 | Option exercise | +619 | $72.68 | $44.99K | 40,653 |
| Wayne Markowitz CVP, JAPAC | Sep 14, 2026 | Tax withholding | −568 | $84.37 | $47.92K | 19,371 |
| Andrew M. Dahl SVP, Corporate Controller | Sep 13, 2026 | Tax withholding | −253 | $84.37 | $21.35K | 14,615 |
| Wayne Markowitz CVP, JAPAC | Sep 11, 2026 | Tax withholding | −355 | $86.77 | $30.80K | 19,939 |
| Daveen Chopra CVP, TMTT, Surgical & IHFM | Sep 11, 2026 | Tax withholding | −398 | $86.77 | $34.53K | 43,926 |
| Daniel J. Lippis CVP, TAVR | Sep 11, 2026 | Sale(10b5-1 plan) | −619 | $87.51 | $54.17K | 40,034 |
| Daniel J. Lippis CVP, TAVR | Sep 11, 2026 | Option exercise | +619 | $72.68 | $44.99K | 40,653 |
| Andrew M. Dahl SVP, Corporate Controller | Aug 31, 2026 | Sale | −544 | $91.06 | $49.54K | 14,868 |
| Annette Bruls CVP, EMEACLA | Aug 28, 2026 | Sale | −2,644 | $89.98 | $237.91K | 17,984 |
| Daveen Chopra CVP, TMTT, Surgical & IHFM | Aug 26, 2026 | Sale | −1,154 | $91.76 | $105.89K | 74,970 |
| Daveen Chopra CVP, TMTT, Surgical & IHFM | Aug 26, 2026 | Sale | −30,646 | $90.99 | $2.79M | 44,324 |
| Daveen Chopra CVP, TMTT, Surgical & IHFM | Aug 26, 2026 | Option exercise | +31,800 | $72.68 | $2.31M | 76,124 |
| Wayne Markowitz CVP, JAPAC | Aug 26, 2026 | Sale | −1,240 | $91.47 | $113.42K | 20,294 |
| Daniel J. Lippis CVP, TAVR | Aug 11, 2026 | Sale(10b5-1 plan) | −619 | $92.03 | $56.97K | 40,034 |
| Daniel J. Lippis CVP, TAVR | Aug 11, 2026 | Option exercise | +619 | $72.68 | $44.99K | 40,653 |
| Wayne Markowitz CVP, JAPAC | Jul 30, 2026 | Sale | −146.31 | $86.03 | $12.59K | 21,534 |
| Wayne Markowitz CVP, JAPAC | Jul 28, 2026 | Sale | −9,628 | $85.06 | $818.96K | 21,680 |
| Wayne Markowitz CVP, JAPAC | Jul 28, 2026 | Option exercise | +9,628 | $74.02 | $712.66K | 31,308 |
| Bernard J. Zovighian CEO, Director | Jul 27, 2026 | Gift | +319.65 | – | – | 11,836 |
| Bernard J. Zovighian CEO, Director | Jul 27, 2026 | Sale | −2,920.55 | $83.93 | $245.12K | 8,916 |
| Bernard J. Zovighian CEO, Director | Jul 27, 2026 | Gift | −319.65 | – | – | 98,845 |
| Annette Bruls CVP, EMEACLA | Jul 11, 2026 | Tax withholding | −109 | $92.21 | $10.05K | 20,628 |
| Daniel J. Lippis CVP, TAVR | Jul 10, 2026 | Option exercise | +619 | $72.68 | $44.99K | 40,653 |
| Daniel J. Lippis CVP, TAVR | Jul 10, 2026 | Sale(10b5-1 plan) | −619 | $91.70 | $56.76K | 40,034 |
| Theodora Mistras CVP, Chief Financial Officer | Jul 9, 2026 | Award | +87,595 | – | – | 87,595 |
| Theodora Mistras CVP, Chief Financial Officer | Jul 9, 2026 | Award | +12,325 | – | – | 99,920 |
| Daniel J. Lippis CVP, TAVR | Jul 7, 2026 | Tax withholding | −377 | $95.18 | $35.88K | 40,034 |
| Daniel J. Lippis CVP, TAVR | Jun 30, 2026 | Option exercise | +619 | $72.68 | $44.99K | 41,030 |
| Daniel J. Lippis CVP, TAVR | Jun 30, 2026 | Sale(10b5-1 plan) | −619 | $91.40 | $56.58K | 40,411 |
| Bernard J. Zovighian CEO, Director | Jun 17, 2026 | Sale(10b5-1 plan) | −523 | $87.92 | $45.98K | 11,517 |
| Andrew M. Dahl SVP, Corporate Controller | May 29, 2026 | Sale | −567.53 | $86.08 | $48.85K | 15,334 |
| Donald E. Bobo Jr CVP,Strategy/Corp Development | May 27, 2026 | Sale | −23,145 | $86.42 | $2.00M | 98,611 |
| Daveen Chopra CVP, TMTT & Surgical | May 22, 2026 | Sale | −1,500 | $84.60 | $126.90K | 44,324 |
| Daniel J. Lippis CVP, TAVR | May 18, 2026 | Sale(10b5-1 plan) | −620 | $81.14 | $50.31K | 40,411 |
| Daniel J. Lippis CVP, TAVR | May 18, 2026 | Option exercise | +620 | $72.68 | $45.06K | 41,031 |
| Donald E. Bobo Jr CVP,Strategy/Corp Development | May 15, 2026 | Sale | −9,968 | $82.07 | $818.07K | 22,798 |
| Donald E. Bobo Jr CVP,Strategy/Corp Development | May 15, 2026 | Sale | −8,000 | $81.82 | $654.56K | 30,970 |
| Bernard J. Zovighian CEO, Director | May 12, 2026 | Gift | −26,640 | – | – | 99,165 |
| Bernard J. Zovighian CEO, Director | May 12, 2026 | Gift | +26,640 | – | – | 48,391 |
| Bernard J. Zovighian CEO, Director | May 12, 2026 | Sale(10b5-1 plan) | −845 | $78.40 | $66.25K | 47,546 |
| Bernard J. Zovighian CEO, Director | May 12, 2026 | Sale(10b5-1 plan) | −35,506 | $77.92 | $2.77M | 12,040 |
| Donald E. Bobo Jr CVP,Strategy/Corp Development | May 11, 2026 | Tax withholding | −7,469 | $79.96 | $597.22K | 32,766 |
| Donald E. Bobo Jr CVP,Strategy/Corp Development | May 11, 2026 | Option exercise | +13,457 | – | – | 40,235 |
| Bernard J. Zovighian CEO, Director | May 11, 2026 | Tax withholding | −26,198 | $79.96 | $2.09M | 125,805 |
| Bernard J. Zovighian CEO, Director | May 11, 2026 | Option exercise | +47,207 | – | – | 157,492 |
| Daveen Chopra CVP, TMTT & Surgical | May 11, 2026 | Tax withholding | −7,538 | $79.96 | $602.74K | 45,824 |
| Daveen Chopra CVP, TMTT & Surgical | May 11, 2026 | Option exercise | +13,583 | – | – | 53,362 |
| Bernard J. Zovighian CEO, Director | May 11, 2026 | Gift | +5,489 | – | – | 21,751 |
| Bernard J. Zovighian CEO, Director | May 11, 2026 | Gift | −5,489 | – | – | 104,796 |
| Wayne Markowitz CVP, JAPAC | May 11, 2026 | Sale | −593 | $79.73 | $47.28K | 21,680 |
| Daniel J. Lippis CVP, TAVR | May 11, 2026 | Tax withholding | −362 | $79.96 | $28.95K | 40,411 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
1.63%
9M shares short
Days to cover
2.8
At 3M shares a day
Change since last report
+0.5%
From 9M shares
Short volume, 20 days
45.3%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Edwards Lifesciences's stock actually held short. Settlement fails (shares not delivered on time) peaked at 4,800 shares on Sep 21, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Daniel J. Lippis Officer | Nov 10, 2026 | 1,857 | $193.59K | Nov 10, 2026 | Employee Stock Option Exercise - See Remarks |
| Bernard J. Zovighian Officer, Director | Nov 9, 2026 | 46,200 | $4.76M | Nov 9, 2026 | Employee Stock Option Exercise - See Remarks |
| Donald E. Bobo Jr Officer | Nov 9, 2026 | 48,900 | $5.04M | Nov 9, 2026 | Employee Stock Option Exercise |
| Andrew M. Dahl Officer | Aug 31, 2026 | 544 | $49.53K | Aug 31, 2026 | Restricted Stock Lapse |
| Annette Bruls Officer | Aug 28, 2026 | 2,644 | $237.91K | Aug 28, 2026 | Restricted Stock Lapse |
| Daveen Chopra Officer | Aug 26, 2026 | 31,800 | $2.89M | Aug 26, 2026 | Employee Stock Option Exercise |
| Wayne Markowitz Officer | Aug 26, 2026 | 1,240 | $113.42K | Aug 26, 2026 | Restricted Stock Lapse |
| Daniel J. Lippis Officer | Aug 11, 2026 | 1,857 | $170.90K | Aug 11, 2026 | Employee Stock Option Exercise - See Remarks |
| Scott B. Ullem Former Affiliate | Jul 30, 2026 | 50,000 | $4.63M | Jul 30, 2026 | RSU / PSU - See Remarks |
| Wayne Markowitz Officer | Jul 30, 2026 | 147 | $12.59K | Jul 30, 2026 | ESPP - See Remarks |
| Wayne Markowitz Officer | Jul 28, 2026 | 9,628 | $818.96K | Jul 28, 2026 | Employee Stock Option Exercise |
| Bernard J. Zovighian Officer, Director | Jul 27, 2026 | 2,921 | $245.13K | Jul 27, 2026 | Exercise & Hold |
| Andrew M. Dahl Officer | May 29, 2026 | 568 | $48.85K | May 29, 2026 | Restricted Stock Lapse |
| Scott B. Ullem Former Affiliate | May 29, 2026 | 64,152 | $5.56M | May 29, 2026 | RSU / PSU - See Remarks |
| Bobo Jr Family Trust Officer | May 27, 2026 | 23,145 | $2.00M | May 27, 2026 | Restricted stock vesting under a registered plan |
See a number that looks wrong?